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Introduction 
1.1 Endometrial cancer: characteristics of lesions 
Endometrial cancer—a tumour originating in the endometrium—is the most common 
gynaecological tumor in developed countries, and its prevalence is increasing (1) As the disease is 
frequently symptomatic at an early stage, endometrial cancer is often diagnosed at stage I.   
Endometrial cancer is the fifth most common cancer in women (4.8% of cancers in women), who 
have a cumulative risk of 1% of developing the disease by age 75 years (1) 
Although endometrial cancer is conventionally thought to be a cancer of the postmenopausal period 
(ie, the sixth and seventh decades of life), 14% of cases are diagnosed in premenopausal women, 5% 
of whom are younger than 40 years (2-4). The increased incidence of endometrial cancer in Europe 
and North America could be related to a greater overall prevalence of obesity and metabolic 
syndromes in these regions, in addition to the ageing of the population (4-7). 
The main risk factor is exposure to endogenous and exogenous oestrogens associated with obesity, 
diabetes, early age at menarche, nulliparity, late-onset menopause, older age (≥55 years), and use of 
tamoxifen (8-13). The relation between diabetes and endometrial cancer is controversial. 
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The levonorgestrel releasing intrauterine system might have a protective effect against endometrial 
malignant transformation (14). 
In the past 30 years, endometrial cancer has been broadly classified into two subtypes on the basis of 
histological characteristics, hormone receptor expression, and grade (table 1) (15). The most common 
subtype is low-grade, endometrioid, diploid, hormone-receptor-positive endometrial cancer, which 
has a good prognosis. Type II endometrial cancers are described as non-endometrioid, high grade, 
aneuploid, TP53-mutated, hormone-receptornegative tumours that are associated with a higher risk of 
metastasis and a poor prognosis (table 1) (16). Clinical presentation and diagnostic assessment 
abnormal uterine bleeding—sometimes associated with vaginal discharge and pyometra—is the most 
frequent symptom of endometrial cancer and is noted in about 90% of patients (usually during 
menopause). Patients with advanced disease might have symptoms similar to those of advanced 
ovarian cancer, such as abdominal or pelvic pain and abdominal distension. Disease can easily be 
diagnosed on the basis of office-based pipelle sampling or other techniques (17, 18). The histological 
information provided by endometrial biopsy is sufficient for preoperative assessment and planning. 
However, pipelle sampling can be infeasible in some postmenopausal women because of cervical 
stenosis. When histological findings from an endometrial biopsy are insufficient to confirm diagnosis, 
cervical dilation and curettage is recommended, although this investigation necessitates anaesthesia 
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and has been associated with disease underestimation (19, 20). A biopsy under hysteroscopy remains 
the gold standard for diagnosis of endometrial cancer and yields higher accuracy than does blind 
dilation and curettage (20, 21). Results of some studies suggested a higher incidence of malignant 
peritoneal cytology at the time of hysterectomy in patients who underwent previous hysteroscopy 
than in those who did not, but no evidence supports an association between diagnostic hysteroscopy 
and worse prognosis (22). Thus, the standard strategy for investigation of abnormal uterine bleeding 
is pelvic ultrasonography with an endometrial biopsy in cases of increased endometrial thickness and 
a hysteroscopy when diagnosis is uncertain (23). A review (24) of 13 studies showed that, in 
menopausal women, an endometrial thickness cutoff of 5 mm on ultrasonography had sensitivity of 
90% and specificity of 54% compared with 98% and 35%, respectively, when the cutoff was reduced 
to 3 mm (24). Estimated cumulative risk of endometrial cancer is 0.96%; the corresponding mortality 
risk is 0.23% and mortality to-incidence ratio is 0.24—lower than that of breast cancer (0.32), ovarian 
cancer (0.63), and uterine cervical cancer (0.55) (1,62). Most endometrial cancers (75%) are 
diagnosed at an early stage (FIGO stages I or II): 5 year overall survival. 
Diabetes mellitus, in particular type II, has long been held as an independent risk factor for 
endometrial cancer, with an approximate doubling of risk (OR 2.1; 95% CI 1.40–3.41) [10]. 
However, the fact that people with type II diabetes mellitus (T2DM) tend to be obese is a 
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confounding factor, and a recent epidemiological study from the United States questioned the 
independent role of T2DM as a risk factor for endometrial cancer [11]. 
Nulliparity and infertility are also classical risk factors for endometrial cancer. Among the causes of 
infertility, polycystic ovarian syndrome (PCOS) seems to be the most important, with an almost 
threefold increase in risk (OR 2.79–2.89) [12]. However, as with diabetes, obesity seems to be a 
confounding factor, and the BMI-adjusted OR is lower  
Although findings from a recently published meta-analysis have verified the efficacy of the 
levonorgestrel intrauterine device (LNG-IUD) in preventing de novo polyps in breast cancer patients 
treated with tamoxifen, there was insufficient evidence to ascertain whether the LNG-IUD was 
associated with any benefit in reducing the incidence of precancerous or cancerous lesions [25]. 
LNG-IUD but preliminary data using such treatment [added to gonadotropin-releasing hormone 
(GnRH) analogues] seem to demonstrate similar remission and recurrence rates as oral progestins 
[26]. Assessment of response must be performed at 6 months with a new D&C and imaging [27]. 
Response rates associated with the conservative management of endometrial carcinoma are ∼75% 
[28, 29], but recurrence rates are 30%–40% [28, 30, 31]. Standard surgery with hysterectomy should 
be proposed to non-responders while maintenance treatment for a further 6 months can be considered 
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in responders who wish to delay pregnancy [32]. Pregnancy is associated with a reduced risk for 
endometrial cancer recurrence [33]. Findings from recent meta-analyses showed that the pooled live 
birth rate among women receiving fertility-preserving treatment for endometrial cancer was 28% and 
reached 39% when assisted reproduction technology was used [28, 34]. Thus, for patients achieving a 
complete response at 6 months, conception must be encouraged and these patients should be referred 
to a fertility clinic. 
For patients with disease recurrence after an initial response, hysterectomy should be proposed as the 
first option. Moreover, given the high rate of recurrence, after completion of childbearing (or after the 
age of potential pregnancy), standard treatment with hysterectomy and salpingo-oophorectomy is 
recommended. Preservation of the ovaries can be considered in selected cases, depending on the 
patient's age and genetic risk factors. 
Endometrial Hyperplasia (EH) is an irregular proliferative process of the endometrial glands that 
leads to an increase in the gland to stroma ratio and can progress to type-I EA if left untreated [35]. In 
the recent 2014 WHO Classification of Tumours of Female Reproductive Organs [35], EH has been 
separated into two groups based upon the presence or absence of cytological atypia, in order to 
highlight the prognostic impact of the presence of atypia on the potentially malignant transformation 
of the lesion.  
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Ideal candidates for conservative management are young women with grade 1, early stage EC with no 
myometrial invasion who are highly motivated to maintain their reproductive potential and 
understand and are willing to accept the risks associated with deviation from the standard of care. 
Although for this patient population, it is important to note that there are a few encouraging reports of 
conservative management of grade 1 EC with superficial myometrial involvement (36) and grade 2 or 
3 EC with no myometrial invasion (37, 38, 39–44). Given the paucity of data, conservatively 
managing higher grade disease should be considered with caution. (45) 
Women with EA or Atypical Endometrial Hyperplasia (AEH) should undergo a total hysterectomy 
with bilateral salpingo-oophorectomy. Although most EAs occur after menopause, approximately 
25% of EAs arise in premenopausal women, with 5% in women aged less than 40 years, of whom 
70% are nulliparous at the time of diagnosis (45-47). In young women, the majority of cases 
correspond to the type-I EA, since these are of endometrioid type, focal, well differentiated and 
limited to endometrium or superficial myometrium (stage FIGO IA, International Federation of 
Gynecology and Obstetrics) (45-47). Consequently, the five year Disease-Free Survival (DFS) rate of 
up to 99.2% in young women is higher than the 5 year DFS rate of 86% observed in women older 
than 45 [45]. Therefore, given the excellent oncologic outcomes associated with early stage EA in 
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young women, the fertility-sparing is an important issue to consider when deciding the most proper 
management to be taken in women diagnosed with EA and AEH who desire pregnancies.  
Atypical Polypoid Adenomyoma (APA) is classified as a mixed epithelial and mesenchymal tumor 
composed of glands showing cytologic atypia and some architectural complexity set in a 
myofibromatous stromal component (35). Although the majority of APAs are benign lesions, some 
authors have reported variable rates of coexistence with or progression to EA (48-52), even in the 
long term (49, 50), thus suggesting recourse to simple hysterectomy in women who do not desire to 
have their fertility preserved (52, 54). However, in the majority of cases, APA occurs in young 
nulliparous women (48-54) and for these patients a standard fertility-sparing treatment has not 
been clearly defined yet. In literature, high rates of recurrence or persistence of the lesion after 
conventional conservative approaches have been reported numerously (51-53), thus suggesting the 
importance of defining an innovative safe and effective conservative treatment. 
 Focal early stage G1-EA, AEH and APA, accordingly to their malignant potential and their 
histological characteristics, all three may be indicated as Atypical Endometrial Lesions (AELs). 
The conservative management of AELs is generally accepted in young women who desire to preserve 
their fertility or in women having serious surgical risk factors. To date, fertility-sparing treatment 
guidelines on EA and AEH have been published (55, 56) though uncertainty still exists in regard to 
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selection criteria and optimal therapeutic and follow-up managements. Furthermore, treatment 
guidelines on APA are still lacking. 
1.2 Clinical presentation and diagnostic assessment 
Abnormal uterine bleeding—sometimes associated with vaginal discharge and pyometra—is the most 
frequent symptom of endometrial cancer and is noted in about 90% of patients (usually during 
menopause). Patients with advanced disease might have symptoms similar to those of advanced 
ovarian cancer, such as abdominal or pelvic pain and abdominal distension. Disease can easily be 
diagnosed on the basis of office-based pipelle sampling or other techniques (57, 58).  
A biopsy under hysteroscopy remains the gold standard for diagnosis of endometrial cancer and yield 
shigher accuracy than does blind dilation and curettage (59,60).  
1.3 Preoperative staging 
The role of preoperative staging is to establish recurrence risk group, mainly on the basis of 
assessment of myometrial and cervical invasion and lymph node metastasis, to define the surgical 
management. MRI is judged the best imaging technique for preoperative staging and has a high 
interobserver concordance (61). Some studies (62,63) suggest that transvaginal ultrasonography by an 
experienced radiologist has similar accuracy to that of MRI for assessment of myometrial and cervical 
12 
 
invasion. Transvaginal ultrasonography is less costly than MRI but cannot be used to assess lymph 
node status. If MRI is not available, CT can be used to determine extrauterine disease (nodal and 
peritoneal). 
Various series have underlined the high accuracy of 18F-fluorodeoxyglucose PET-CT in detection of 
myometrial and cervical invasion and lymph node metastatic disease. However, although its 
prognostic value has been shown for advanced stage endometrial cancer, use in preoperative staging 
in early stage disease remains questionable (64, 65). Emerging molecular imaging techniques, such as 
hybrid PET/MRI, could improve diagnostic accuracy through superior soft tissue contrast, 
multiplanar image acquisition, and functional imaging (66). 
1.4 Staging classifications, clinical and biological prognostic factors 
The main goal of staging classifications is to define groups of patients with similar outlooks to 
standardise management and allow comparisons of therapeutic strategies. The 2009 International 
Federation of Gynecology and Obstetrics (FIGO) and the TNM classifications are the most-adopted 
classifications (table 1) (67, 68). They are based on surgical staging and include assessment of the 
extent of myometrial invasion and local and distant metastatic disease—overriding prognostic factors 
in endometrial cancer (67, 69, 70). 
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Other prognostic factors not included in the FIGO or TNM classifications have also been identified: 
histological type and grade, the patient’s age, tumour size, and lymphovascular space involvement.  
Table 1: FIGO and TNM classification of endometrial cancer, by surgical and histological characteristics 
 
1.5 Survival 
Estimated cumulative risk of endometrial cancer is 0,96%; the corresponding mortality risk is 0,23% 
and mortality - to- incidence ratio is 0,24 —lower than that of breast cancer (0,32), ovarian cancer 
(0,63), and uterine cervical cancer (0,55) (71, 72). Most endometrial cancers (75%) are diagnosed at 
an early stage (FIGO stages I or II): 5 year overall survival anges from 74% to 91%;5,63 for FIGO 
stage III, 5 year overall survival is 57–66%, and for FIGO stage IV disease is 20–26% (73, 74). 5 year 
disease-free survival is estimated at 90% in patients without lymph node metastasis, 60–70% in those 
with pelvic lymph node metastasis, and 30–40% in those with para-aortic lymph node metastasis. 
However, a substantial proportion of patients with endometrial cancer die from other health 
conditions as these patients often have several comorbidities. 
Survival is dependent on other predictive factors, such as the tumour grade, age, comorbidities, 
tumour diameter, American Society of Anesthesiologists score, lymphovascular space involvement, 
and postoperative complications at 30 days. (75, 76–81).  
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1.6 Principles of surgical treatment 
Total hysterectomy and removal of both tubes and ovaries is the standard treatment for apparent stage 
I endometrial cancer and is effective in most cases. Alternatives to primary hysterectomy in women 
who want to preserve their fertility have been comprehensively reviewed (82). Hysterectomy and 
adnexectomy can be done with minimally invasive techniques (laparoscopy or robot-assisted 
surgery), vaginally, or laparotomically. The safety of laparoscopy has been shown in randomised 
clinical trials (83, 84) and is associated with shorter hospital stays and fewer postoperative 
complications than laparotomy.  
Laparoscopic or robotic approaches should be avoided in cases of bulky uterine malignant disease 
that might necessite morcellation, because morcellation can lead to tumour spillage, increasing local 
or peritoneal recurrence and thereby affecting survival. Although simple total hysterectomy is 
sufficient for most women, radical hysterectomy is sometimes done in cases of gross cervical 
invasion or when uncertainty exists about whether the primary tumour is endocervical or endometrial 
in origin. Surgical staging for endometrial cancer includes careful assessment of the peritoneal 
surfaces. Omental and peritoneal biopsies are commonly done in high-risk disease. 
1.7 Lymphadenectomy and sentinel node biopsy 
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Surgical assessment of lymph nodes for staging at primary surgery remains one of the most varied 
practices worldwide, ranging from no nodal assessment, to sentinel node mapping, to complete pelvic 
and aortic lymphadenectomy up to the renal vessels. Most clinicians agree that excision or biopsy of 
suspicious or enlarged lymph nodes in the pelvic or para-aortic regions is important to exclude nodal 
metastatic disease. Pelvic nodal dissection and pathological assessment continue to be important 
aspects of surgical staging for apparent stageIendometrialcancerinmanypractices,andmight be based 
on preoperative criteria such as histology, grade, or MRI findings, or on intraoperative histology. 
Para-aortic nodal assessment from the intramesenteric and infrarenal regions is also done for staging 
selected high-risk tumours, such as deeply invasive lesions, high-grade endometrioid endometrial 
cancers, and type II disease (85). 
The extent of lymphadenectomy varies tremendously between practices and practitioners. However, 
no survival advantage has yet been associated with staging lymphadenectomy in prospective, 
randomised, clinical trials. Furthermore, between 8% and 50% of patients develop limb 
lymphoedema, depending on the number of nodes removed, extent of lymphadenectomy, and use of 
adjuvant treatment (86). Most available retrospective evidence suggesting a survival advantage with 
lymphadenectomy is from historical series of selected patients and contrasts sharply with findings 
from prospective randomised trials (87, 88). 
16 
 
Type II endometrial cancers account for 10–15% of endometrial cancers but cause 40% of deaths 
because of the high incidence of associated extrauterine disease, especially lymph node metastasis. 
Surgical manage- ment includes hysterectomy with bilateral salpingo- oophorectomy, pelvic and 
para-aortic lymphadenectomy, omentectomy, and peritoneal biopsies (89-93). 
 
2. I STUDY: Fertility-sparing treatment of atypical endometrial lesions in young women 
We have conducted a retrospective study that assess safety and effectiveness of combined 
hysteroscopic and medical treatments of AELs in young women who desired to preserve their own 
fertility. 
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2.1 Materials and Methods 
This was a multi-unit retrospective case series study carried out on young women referred to two 
Operative Units of the Department of Obstetrics and Gynecology of the "Federico II" University 
(Naples), diagnosed with AELs and treated by fertility-sparing combined hysteroscopic and medical 
treatments.  
After the approval by the institutional review board, we collected data on the clinical history of 
patients, and on the diagnostic and therapeutic procedures performed, through querying electronic 
databases and reviewing individual medical records available from 2007 to 2016.  
We analyzed sixty-nine young women diagnosed with AELs and treated by combined hysteroscopic 
and medical treatment between 2007 and 2016. All patients underwent gynecological examination 
and Transvaginal-Ultrasonography (TV-USG), and the histological diagnosis of AEL was obtained 
by endometrial biopsy performed during Office Hysteroscopy (OfH) using miniaturizing instruments 
(grasping forceps).  
Of these sixty-nine women, thirteen were diagnosed with Atypical Polypoid Adenomyoma (APA); 
forty-two with Atypical Endometrial Hyperplasia (AEH); fourteen with focal well differentiated 
Endometrial Adenocarcinoma (G1-EA). The patients who had been diagnosed with EA repeated TV-
USG and performed contrast-enhanced abdomen and pelvis Magnetic Resonance to exclude 
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myometrial or cervical invasion and extrauterine metastases. In these patients serum CA-125 and 
CA19.9 levels were also evaluated.  
Every woman who underwent conservative treatment was motivated to preserve her own fertility and 
was counseled for the risk of recurrence or progression of diseases associated with deviation from 
demolitive surgical approaches. 
Patients diagnosed with APA (n=13) or focal G1-EA (n=14) were treated by Hysteroscopic Resection 
(HR) in three steps: 1) removal of the exophytic tumor lesion; 2) removal of the endometrium 
adjacent to the lesion; and 3) removal of the muscle layer beneath the lesion, according to the 
technique first described by Mazzon et al. [17]. The patients diagnosed with AEH (n=42) were treated 
by superficial endometrial resection (i.e. preserving the basal layer of the endometrium). All the 
operative hysteroscopic procedures were performed by expert surgeons (A.D.S.S. and A.M.) under 
general anesthesia. The cervix was dilated to 10 mm with Hegar’s dilator, and a 27 Fr bipolar 
resectoscope (ETHICON INC, Sommerville, New Jersey, USA) with 12° or 30° lens was introduced. 
The uterus was distended with normal saline and a 4-mm cutting loop electrode and Versapulse 
modality were used. Immediately after the Operative Hysteroscopy (OH), a Levonorgestrel-
Intrauterine Device (LNG-IUD)  ( Mirena, Bayer HealthCare, PA, USA.) was inserted in all patients.  
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For every patient we collected all the pathology reports of hysteroscopic biopsies performed during 
the follow-up period of 24 months, as well as data on eventual pregnancies. For one patient diagnosed 
with AEH, who experienced relapse at 24 months and who was submitted to a second cycle treatment 
(R
IV
, Table 1), pathology reports were collected beyond the 24 months in order to assess her clinical 
status.  
The histological examinations were classified as Complete Response (CR), Partial Response (PR), 
Stable Disease (SD) and Progression (P). CR was defined as absence of any AEL; PR as regression of 
EA to AEH and regression of AEH to hyperplasia without atypia; SD as persistence of pre-treatment 
lesions; P as worsening of the histological grade of lesions. Relapse (R) was defined as the presence 
of AELs after CR had been previously achieved. In this case series we retrospectively evaluated the 
regression, relapse, and pregnancy rates during a follow-up time of 24 months. 
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Table 1: Oncologic and reproductive outcomes of patients with AELs conservatively treated 
OfH 
diagnosi
s 
n
° 
Treat
ment 
Response at 3 
months 
Response at 6 
months 
Response at 12 
months 
Response at 24 months 
Pregnan
cies (n° 
of 
patients
) 
CR PR 
SD or 
P 
CR PR 
SD or 
P 
CR PR 
SD 
or P 
R CR PR 
SD or 
P 
R 
APA 
1
3 
HR +  
LNG-
IUD 
12 - 1 SD 13 - -  13 - - - 
12 CR, 
1† 
- - - 
3 NSFTD  
1 ECS 
AEH 
4
2 
REA + 
LNG-
IUD 
38 2 2 SD 38 2 2 SD 
34, 
4† 
3 1SD - 31, 5† 
2, 
1† 
1† 
RIII, 
RIV 
4 NSFTD 
2 ECS 
Focal 
G1-EA 
1
4 
HR +  
LNG-
IUD 
11 1 
1SD, 1 
P* 
11 1 1SD   9 1 1SD 
RI, 
RII
 9, 1† 1 
2 
SD**  
- 0 
 
OfH: Office Hysteroscopy; APA (Atypical Polypoid Adenomyoma); AEH (Atypical Endometrial 
Hyperplasia); G1-EA (well differentiated Endometrial Adenocarcinoma); HR (Hysteroscopic Resection) in 
three steps; REA (Resectoscopic Endometrial Ablation); LNG-IUD (Levonorgestrel - Intrauterine Device); 
CR: Complete Response; PR: Partial Response; SD: Stable Disease; P: Progression; R: Relapse; RI: patient 
underwent re-treatment with HR and LNG-IUD and achieved a second CR, response maintained at 24 
months; RII: patient underwent re-treatment with HR and LNG-IUD, however she showed SD and was 
consequently submitted to demolitive surgery at 24 months; RIII: definitive surgery at 24 months; RIV: 
patient underwent re-treatment with REA and LNG-IUD and achieved a second CR, response maintained 
at 3 and 6 months after second-cycle treatment; NSFTD: Normal Spontaneous Full Term Delivery; ECS: 
Elective Caesarean Section at 39 weeks. 
 
† data not available because patients had not reached the follow-up target time; * Definitive surgery at 
3 months; ** Definitive surgery at 24 months (two patients with focal G1-EA and SD; one patient with 
G1-EA/AEH and P) 
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Figure 1: Schematic representation of patients 
 
APA (Atypical Polypoid Adenomyoma); AEH (Atypical Endometrial Hyperplasia); G1-EA (well 
differentiated Endometrial Adenocarcinoma); HR (Hysteroscopic Resection) in three steps; REA 
(Resectoscopic Endometrial Ablation); LNG-IUD (Levonorgestrel - Intrauterine Device); CR: Complete 
Response; PR: Partial Response; SD: Stable Disease; P: Progression; R: Relapse. TAH: Total Abdominal 
Hysterectomy (with bilateral salpingo-oophorectomy). 
 
Dotted line: patients who had not reached the follow-up target time. 
 
  
38 CR 2 PR 2 SD 
38 CR 2 PR 2 SD 
34 CR 3 PR 1 SD 
4 
31 CR 2 PR 
1 1 1 
RIII RIV 
II cycle 
11 CR 1 PR 1 SD 
11 CR 1 PR 1 SD 
1 PR 1 SD 9 CR 
1 PR 
RI RII 
42 AEH 14 Focal G1-EA 
9 CR 
1 
2 SD 
1 P 12 CR 1 SD 
13 CR 
13 CR 
12 CR 
1 
13 APA 
3 mo. 
6 mo. 
12 mo. 
24 mo. 
HR + LNG-IUD REA + LNG-IUD HR + LNG-IUD 
TAH 
CR 
II cycle 
TAH 
TAH 
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2.2 Results 
A total of sixty-nine patients were analyzed in this retrospective study. The mean age was 32.6±3.5 
yrs (range 20-44) and the mean Body Mass Index was 25.9±5.3 Kg/m
2
. Twenty-nine patients (42%) 
had not had previous pregnancies and fifteen of them (51.7%) referred primary infertility. None of the 
enrolled patients had any complications or adverse effects related to the endoscopic surgery or the 
hormonal therapy. 
Histological analysis of surgical specimen obtained by OH confirmed in all patients pre-treatment 
hysteroscopic diagnosis and, in patients who had been diagnosed with G1-EA, the absence of 
myometrial infiltration. 
The oncologic and reproductive outcomes are detailed in Table 1. The schematic representation of 
patients according to their treatment and follow-up is given in Figure 1. 
At 3 months of follow-up, data on sixty-nine patients were collected. Sixty-one patients (88.4%) 
obtained a CR, three patients (4.3%) obtained a PR, four patients (5.8%) showed SD, while one 
patient (1.5%), who had been diagnosed with focal EA-G1, showed P of the lesion and underwent 
definitive surgery: the pathology report of the surgery specimen indicated Stage FIGO IA G3-EA 
(lesion invaded less than half of myometrium).  
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At 6 months of follow-up, one patient diagnosed with APA, who had previously shown SD, achieved 
a CR. 
At 12 months of follow-up, one patient diagnosed with AEH, who had previously shown SD, 
achieved a PR. Two patients first diagnosed with focal G1-EA, both of whom had previously 
achieved a CR, showed R and were re-treated with a second-cycle HR and LNG-IUD: the first patient 
(R
I
, Figure 1) achieved and maintained a CR at 3, 6 and 12 months after second-cycle treatment; the 
second one (R
II
, Figure 1) showed SD at 3, 6 and 12 months after second-cycle treatment and 
underwent definitive surgery at 24 months of follow-up.  
At 24 months of follow-up, two women, first diagnosed with focal G1-EA, were submitted to 
definitive surgery: one had shown SD since the third month of follow-up; the other (R
II
, Figure 1) has 
been already described above. One patient (R
III
, Figure 1) first diagnosed with AEH, who had 
previously achieved a CR, showed R and underwent definitive surgery. Another patient (R
IV
, Figure 
1) first diagnosed with AEH, who had previously achieved a CR, showed R and underwent re-
treatment with a second-cycle REA and LNG-IUD; she achieved and maintained a CR at 3 and 6 
months after re-treatment.  
Follow-up data on nine patients were incomplete. These patients were detailed as follows: one APA 
patient with CR at 12 months; four AEH patients with CR at 6 months; one AEH patient with CR at 
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12 months; one AEH patient with PR at 12 months; one AEH patient with SD at 12 months; one focal 
G1-EA patient with CR at 12 months.  
Till the end of follow-up period, out of the sixty-two patients who had achieved a CR, 8.2% (4/49) of 
patients with AEH or EA and 0% (0/13) of patients with APA showed relapse of lesions. 
At 12 months of follow-up, the complete responders were proposed to remove the LNG-IUD and 
attempt to conceive. Out of the fifty-six patients who had achieved and maintained CR, twenty-five 
(44.6%) removed LNG-IUD. The remaining thirty-one patients (55.4%), although had been motivated 
to preserve their fertility, did not wish to get pregnant at the time of survey; therefore, they decided to 
leave the LNG-IUD in situ as contraceptive device. Among patients who had removed LNG-IUD, ten 
patients (40%) became pregnant after natural conception in the following twelve months. Three 
babies were born by caesarean section at 39 weeks of gestation, and seven were born at term 
spontaneously. No complications occurred during pregnancy and delivery.  
 
 
  
25 
 
2.3 Discussion 
In this retrospective study we analyzed the oncologic and reproductive outcomes of patients who had 
been diagnosed with AELs and treated by combined OH and hormonal therapy.  
The efficacy and safety of oral and intrauterine-released progestins as fertility-sparing treatments in 
patients with early stage G1-EA and AEH have been evaluated in many studies, even recently (94-
98). The most contemporary meta-analysis demonstrated that the women with EA or AEH managed 
with progestins had a pooled CR rate of 71%, though the authors did not report the separate CR rates 
of the two atypical lesions (99). A previous meta-analysis on women with EA or AEH conservatively 
treated reported a pooled regression rate of 76.2% for EA and 85.6% for AEH (100), although the 
authors did not perform a subgroup analysis for each of several treatments included (oral progestins, 
LNG-IUD, HR). However, the major effectiveness of LNG-IUD compared to oral progestins in 
women with AEH was observed in a meta-analysis (101) and in a comparative cohort study (102) by 
the same author. By contrast, in women with early stage EA the use of LNG-IUD was found to be 
similarly effective compared to oral progestins (103), although the use of LNG-IUD alone in EA 
patients has not been extensively reviewed as oral progestins. More recently, HR of EA and AEH 
followed by oral or intrauterine-released progestins has been demonstrated to be an effective fertility-
sparing treatment (104-108).  
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In our series, all women with focal early stage G1-EA had undergone HR of the lesion in three steps 
followed by insertion of LNG-IUD. This approach resulted in an overall response rate of 85.7% 
(12/14) and in a CR rate of 78.6% (11/14), while two patients did not respond to the first-cycle 
treatment and were consequently submitted to definitive surgery: the first one had shown progressive 
disease at 3 months; the second one had shown SD after 24 months of conservative therapy. At our 
knowledge, this is the second largest series of women with focal early stage G1-EA treated by such a 
combined conservative technique, after Falcone et al. (108), and our results, although not as 
noticeable as those reported by other authors (104-108), essentially confirmed the major effectiveness 
of such combined approach. In fact, the CR rate achieved in our series (78.6%) was within the range 
of 78% to 100% CR reported by Falcone et al. (108) in their Literature review of the studies on 
combined therapies, and was higher than those reported in most recent studies and meta-analyses on 
progestin therapies alone (97, 99, 100), as partly detailed above. 
In contrast with EA, limited data are available in literature on the combined surgical and medical 
treatment of AEH (106-110). Shan et al. (110) reported a CR rate of 83.3% in patients with AEH 
treated by extensive endometrial hysteroscopic curettage followed by Megestrol Acetate. More 
recently, De Marzi et al. (106) reported a CR rate of 100% in patients with AEH treated by HR of 
hyperplastic areas and subsequent hormonal therapy. In our series, all patients diagnosed with AEH 
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underwent superficial endometrial resection followed by insertion of LNG-IUD. As already described 
by Shan et al. (110), this technique allows the removal of most, if not all, cancer tissue, thus probably 
increasing the responsiveness to progestin treatments. Furthermore, the preservation of the basal layer 
of the endometrium allows the complete regeneration of endometrium after the end of the medical 
treatment, thus preserving women's childbearing potential. Our combined approach resulted in an 
overall response rate of 95.2% (40/42) and in a CR rate of 90.5% (38/42). At our knowledge, this is 
the largest series of patients with AEH treated by such a combined treatment and the CR rate 
achieved was higher than those reported in recent studies on women with AEH treated by oral 
progestins alone (range 46.2%-81.8%) (117,118) and by LNG-IUD alone (range 67%-76.2) 
(117,118). However, the high CR rates, up to 100%, observed in women with AEH treated by LNG-
IUD alone and reported in older and more recent studies (111-113), would indicate the need for 
further comparative cohort studies. 
Unlike other AELs, there are few data available in Literature on conservative treatment of patients 
with APA. In the past, blunt curettage had represented the conventional conservative treatment but 
some authors described its limitations (119-120). HR had been therefore recommended by many 
authors (119, 54, 114, 115) as conservative treatment for APA. The oncologic and reproductive 
outcomes of a hormonal therapy for APA have been recently reported (121). At the best of our 
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knowledge, this is the first case series of patients with APA treated by HR of the lesion and 
subsequent insertion of LNG-IUD. At 12 months of follow-up, 100% of patients (13/13) diagnosed 
with APA achieved a CR. Matzumoto et al. (52) had already described the superiority of HR over the 
blunt curettage after having compared respective recurrence rates (10% for HR and 36.4% for blunt 
curettage), and our results also confirmed the higher effectiveness of hysteroscopic surgery.  
With regard to pregnancy outcome, a meta-analysis of women with AE and AEH, managed with 
fertility-sparing treatments, found pooled live birth rates of 28% and 26.3% respectively (100). In 
recent studies on women treated by hysteroscopic and medical treatment, De Marzi et al. (106) and 
Falcone et al. (108) reported a pooled live birth rate of 21.7% and 50% respectively. In our series no 
patient with EA got pregnant while 14.3% (6/42) of patients with AEH did, although this rate would 
have been higher (17.1%) if we had considered only the patients who had reached the 24-month 
follow-up (6/35). These low rates could be explained by the more restrictive follow-up time 
retrospectively analyzed in our series compared to the mean follow-up times of other authors (104, 
108). Furthermore, in our series 30.7% (4/13) of patients diagnosed with APA got pregnant within 24 
months. This was consistent with the live birth rates reported by Nomura et al. [8] (22.2%) and 
Grimbizis et al. (49) (22.2%) in most recent studies on patients with APA conservatively treated.  
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With regard to recurrences, the most contemporary meta-analysis (99) showed an overall Relapse 
Rate (RR) of 20% in women with AEH or early-EA successfully treated by progestins, over a median 
follow-up time ranging from 0.3 to 98 months, and the RR was higher in women treated by oral 
progestins than those treated by intrauterine-released progestins. This RR seems to be higher than the 
8.2% (4/49) RR observed in our series of patients with AEH or early-AE.  
Concerning only the AEH, in our series two patients first diagnosed with AEH (5.3%, 2/38), who 
previously achieved CR, were found to have a Relapse of the lesion at 24 months (R
III
, R
IV
, Table 1). 
In a cohort study on patients with AEH medically treated, relapse of hyperplasia occurred in 27.3% of 
women treated by LNG-IUD and 50% of women treated by oral progestins (116), and a consistent 
number of patients relapsed during the first 24 months. Moreover, the risk of relapse of AEH is 
especially high in the first 2 years from diagnosis (104). In the most recent study on women with 
AEH treated by combined approach, De Marzi et al. (106) reported a RR of 0% (0/20) after a mean 
follow-up time of 25 months. Taking into account all the previous observations, our results might 
confirm the major safety of the combined treatment compared to the progestin therapies alone.  
Considering only the early-EA, in our series two patients first diagnosed with G1-EA (2/11, 18.2%), 
who had previously achieved CR, were found to have a Relapse of the lesions at 12 months (R
I
, R
II
, 
Table 1). A meta-analysis of seven studies (103) reported a 24.6% RR in women with EA treated by 
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progestins alone during a mean follow-up of 27 months. Another contemporary meta-analysis (116) 
on women with early EA showed a pooled recurrence rate of 40.6% after successful fertility-sparing 
therapy, although the median follow-up time of the studies included ranged from 11 to 76.5 months, 
and thus it was longer than ours. Our findings suggest that the combined treatment might be safer 
than progestin therapies alone, thus confirming what was described by other authors. In fact, Falcone 
et al. (108) had already observed that the pooled recurrence rate of EA in studies on women treated by 
combined therapy (16%) was lower than that reported in most recent studies on progestin therapies 
alone (32%).  
In regard with APA, among most recent studies, Nomura et al. (121) reported a RR of 44.4% and the 
median time to recurrence was 5 months; Grigoris et al. (122) reported two relapses after 5 months 
and 5 years respectively; Matzumoto et al. (119) observed a RR of 23.8% during a mean follow up of 
38.9 months. In our series after 24 months of follow-up no patient experienced recurrence of lesion, 
suggesting that HR followed by hormonal adjuvant therapy might be proposed as a safe conservative 
treatment. 
In conclusion, taking into account the oncologic and reproductive outcomes, we believe that OH with 
subsequent insertion of LNG-IUD could be considered an efficient and safe approach in the 
management of AELs in young women who wish to preserve their own fertility. However larger 
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series and randomized clinical trials are needed to further assess the effectiveness of such combined 
treatments. 
3. Endometrial cancer and PCOS 
A state of hyperestrogenism with endometrial hyperplasia are the etiopathogenetic causes of 
endometrial cancer, both in early and advanced disease stages, (ie excessive proliferation of the 
endometrial mucosa). Endometrial hyperplasia is mostly the result of persistent and prolonged 
estrogenic stimulation of endometrium (absolute or relative hyperestogenesis). Endogenous absolute 
hyperestrogenic conditions are determined by obesity, the presence of polycystic ovary syndrome 
(PCOS) and the presence of granular or adrenal cell tumors.  
A growing scientific interest is emerging in endocrinology and gynecologic oncology in assessing the 
risk of endometrial carcinoma in women with PCOS. Since the risk of endometrial cancer (CE) is 
strongly associated with high circulating levels of estrogen, all pathological conditions leading to this 
hormone may promote proliferation of endometriosis. This is the case for women with PCOS who 
show a high risk of developing atypical endometrial hyperplasia (EH), considered precancerous 
lesion, which may progress toward the development of endometrial cancer. However, an assessment 
of the prevalence of atypical endometrial hyperplasia in women with PCOS remains a widely debated 
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matter. The existing biological relationship between PCOS and CE, though still unclear, refers to a 
combination of complex reproductive and metabolic disorders: in fact, chronic anovulation, obesity 
and hyperinsulinemia also cause progesterone deficiency. As a result, the endometrium tends to 
remain in a proliferative state of estrogen dependent, thus increasing the risk of developing 
endometrial cancer (123). In addition, insulin resistance, other metabolic impairment in PCOS, results 
in an increase in IGF-I, and synergistically play a key role in the proliferation and differentiation of 
endometrial cells, promoting EC development (124,125). Many studies in the literature confirm a 
higher risk of developing an endometrial cancer in women with PCOS (124-128). Indeed, 
observational studies have reported that women with PCOS have a threefold higher risk of developing 
a well-differentiated endometrial carcinoma and this has recently been reported in a meta-analysis by 
Haoula et al (124) which confirmed that the risk of developing an endometrial cancer is three times 
higher than in the general population.  
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders of the 
reproductive age. It is a complex, multidimensional endocrine-metabolic disorder that has profound 
repercussions on women's health not only in fertile ages but throughout the entire life span (129). 
PCOS affects about 4 to 8% of women of childbearing age. According to the European Society of 
Human Reproduction and Embriology (ESHRE) and the American Society of Reproductive Medicine 
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(ASRM), the diagnosis is based on the presence of at least two of the following three symptoms: 
oligo-anovulation or anovulation, hyperandrogenism and/or hyperandrogenemia, polycystic ovaries. 
One of the major disorders caused by PCOS is anovulatory infertility. There are several methods to 
treat anovulatory infertility by PCOS, and these include both simple interventions such as lifestyle 
changes, and more complex interventions such as laparoscopic ovarian drilling (LOD). Reduction in 
body weight is considered first-line therapy in patients with overweight and obese PCOS associated 
with oral sensitizers such as metformin (129). Currently, the high-grade drug for induction of 
ovulation in patients with PCOS anovulatory infertility remains clomiphene citrate (CC) (130) and 
has been around for nearly 50 years. The CC has good management, is inexpensive and has minimal 
side effects. Acting as an estrogen receptor antagonist in the hypothalamus and at the anterior 
pituitary, increases FSH secretion and induces ovulation in 75-80% of patients, but only 35-40% of 
patients are able to get pregnant (131). The discrepancy between the percentage of response to 
induction of ovulation and pregnancy rates is thought to be mainly related to its anti-estrogenic 
activity on cervical function and endometrial receptivity. In addition, increased CC secretion induced 
by CC, which does not occur with FSH administration, may also reduce the probability of conception 
(132). 
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In addition, although limited, there are some studies that show how CC can, in the long term, double 
the risk of developing a endometrial cancer (133). Indeed, studies claim that the CC has a structure 
similar to tamoxifen (SERM) (134, 135) and the latter is recognized as a potentially predisposing 
factor to endometrial hyperplasia and therefore a precursor to endometrial cancer. CC resistance 
(ovarian failure with maximal doses, 150 mg per day for 5 days for at least 3 consecutive cycles) or 
failure of CC, there is a second line of treatment for ovarian stimulation with injectable gonadotropins 
(FSH). However, their use is burdened with some disadvantages such as OHSS (Ovarian Hyper-
Stimulation Syndrome) or multiple pregnancies (132). Laparoscopic Ovarian Drilling (LOD) has 
been shown to be a viable therapeutic alternative for patients with PCOS-resistant patients, for 
patients who are hyper-responsive to gonadotrophin therapy and for patients who need diagnostic 
laparoscopy for infertility (136). A recent Cochrane has demonstrated the efficacy of LOD in terms of 
pregnancy rate in the absence of increased risk of multiple pregnancies or ovarian hyperstimulation 
(137). The mechanism of action is that the destruction of ovarian follicles and part of ovarian stroma 
results in local and systemic reduction of androgens and inhibition levels followed by an increase in 
FSH levels that promotes follicular maturation and subsequent ovulation (138). However, two major 
disadvantages do not allow laparoscopic ovarian drilling to be considered the first line of PCOS 
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treatment: the risk inherent in surgery as such and the risk associated with the formation of post-
operative adherence that may further interfere with fertility .  
Therefore, considering the interest addressed to PCOS in a study by the title “Post-operative ovarian 
adhesion formation after ovarian drilling: a randomized study comparing conventional laparoscopy 
and transvaginal hydrolaparoscopy”, we conducted a review of the literature and described a new 
mini-invasive surgical approach to ovarian drilling in patients with PCIs anovulatory infertility, using 
the Transvaginal Hydrolaparoscopy technique to reduce the rate of ovarian adherence. From the 
results we have shown that patients undergoing ovarian drilling by THL showed a reduction in 
adhesion formation compared to patients treated with classical technique (LOD) (15.5% vs. 70.2%). 
3.1 II STUDY: Post-operative ovarian adhesion formation after ovarian drilling: a randomized 
study comparing conventional laparoscopy and transvaginal hydrolaparoscopy 
Laparoscopic ovarian drilling (LOD) is an alternative method to induce ovulation in CC-resistant  
anovulatory patients affected by PCOS, as an alternative to gonadotropins (136, 139). However, there 
are concerns regarding the long-term effects on ovarian function of LOD, in particular iatrogenic 
adhesions and decreased ovarian reserve (DOR), which may potentially jeopardize future fertility 
(140). Fernandez et al. (141) suggested a new approach for ovarian drilling using Transvginal 
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hydrolaparoscopy (THL). They showed THL to be a safe and feasible alternative procedure to LOD. 
Since THL could be considered less invasive than laparoscopy, infertile women with PCOS may 
benefit from ovarian surgery performed using a mini-invasive approach that may limit post-operative 
ovarian adhesions and return to daily activities.        
Aim of our study was to compare conventional LOD with THL ovarian drilling in terms of ovarian 
adhesion formation, evaluated using office THL during follow up. 
3.2 Materials and methods 
This open, randomized study was performed at the Department of Obstetrics and Gynecology of the 
University of Naples “Federico II”. During the period from December 2009 and July 2015, 286 
patients CC-resistant with PCOS were considered for inclusion in the study. Inclusion criteria were: 
age 18-40 years; PCOS diagnosis according to 2003 Rotterdam criteria (142). Exclusion criteria: 
endocrine anomalies other than PCOS (congenital adrenal hyperplasia, Cushing syndrome, previous 
administration of androgens, and androgen secreting tumor - AST);  any disease potentially 
responsible of ovarian adhesion (i.e., ovarian cyst, endometriosis, pelvic infection, pelvic 
inflammatory disease), previous abdominal or pelvic surgery, presence of adhesions, fixed retroverted 
uterus; lateral displacement of the cervix; suspect pelvic tumor; vaginal infection; abnormalities at 
vaginal examination and transvaginal ultrasound; psychiatric condition impairing the ability of the 
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patients to cooperate, obliteration of the pouch of Douglas or inability to perform the vaginal exam 
and any other contraindication to THL or laparoscopy.   
The study design was approved by the institutional review board (IRB), and written informed consent 
was obtained from each patient.   
The flow of patients throughout the study is illustrated in Figure 2.  
Two hundred and forty- six patients satisfied the inclusion criteria. Forty patients were not included in 
the study: twelve refused to undergo the randomization process and twenty-eight  did not meet the 
inclusion criteria. Two hundred and forty- six patients were randomized into two groups in a 1:1 ratio 
by use of a randomization list generated by a computer with blocks of 4. One hundred and twenty-
three patients were scheduled to undergo LOD and 123 to undergo THL ovarian drilling. Before the 
procedure, all patients underwent a clinical examination,  routine preoperative biochemical testing 
and a transvaginal pelvic ultrasound scan. The allocation sequence was concealed from the 
researchers, who enrolled and assessed the participants and attached a sequentially numbered, opaque, 
sealed, and stapled envelope containing the allocated treatment to the clinical record of the patient 
after having signed the informed consent. The envelope was opened on the morning of the procedure. 
Patients and surgeon were not blinded to the procedure performed because concealment was not 
possible due to the differences in the procedures.    
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All procedure were performed by a single surgeon who already performed more than 50 procedures 
before the beginning of the study. Patients in group A (n = 123) underwent ovarian drilling by 
laparoscopy under general anesthesia, while patients in group B (n = 123) underwent ovarian drilling 
with THL under spinal anesthesia.      
All subjects received antibiotic prophylaxis immediately before the procedure (cefazolin 2 g 
intravenously). Laparoscopic ovarian cautery was performed using a traditional 10- mm endoscope 
inserted through the primary sub umbilical trocar, with two additional 5-mm trocars in the lower 
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abdomen. A grasping forceps was introduced through one of the lower abdominal 5 mm trocars to 
grasp the utero-ovarian ligament and lift the ovary away from the bowel. The other access was used to 
introduce the unipolar needle. The whole length of the needle was inserted with a 90° angle into the 
ovary using  an unipolar needle electrode with a power setting of 40 W for 4-5 seconds set at 30 W 
per ovary (the lowest recommended dose) (143). The ovarian punctures were uniformly distributed 
throughout the ovarian surfaces. Three to six punctures per ovary were performed depending on the 
size of the ovary, since it was demonstrated that these numbers yield statistically significantly higher 
ovulation and pregnancy rates (144). THL was performed with the patients in gynecologic position, 
under spinal anesthesia. Using a Verres needle, 300 mL of normal saline solution was instilled into 
the peritoneal cavity through the posterior vaginal fornix. A specially designed needle dilating trocar 
system with a total diameter of 3.9 mm was placed 10–20 mm below the insertion of the posterior 
vaginal wall to the cervix. A 2.7 mm diameter semi rigid endoscope with a 3.5 mm sheath was used 
with an optical angle of  30° to visualize the pelvic cavity (Karl Storz, GmbH & Co., Tuttlingen, 
Germany). The posterior aspect of the uterus was examined first, followed by the ovary and fallopian 
tube on each side. A bipolar electrosurgical probe (Versapoint- Gynecare Inc., menlo Park, CA) was 
introduced through the auxiliary channel of the sheath. By using this probe, the ovarian cortex was 
drilled in 3 to 6 points per ovary, using a power setting of 110 to 130 W.     
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 The informed consent that the patients signed before being included in the study stated the 
possibility to undergo laparoscopy or THL with the same probability. Moreover, the informed consent 
states the possibility of converting the procedure to laparotomy (or laparoscopy for the patients 
allocated to the THL group).       
Six months after the procedure, all patients underwent trans-vaginal ultrasound scan and evaluation of 
any complication. Moreover, all patients were offered to undergo office transvaginal 
hydrolaparoscopy (THL) under local anesthesia to evaluate the presence of adhesions. After office 
THL follow-up, the participants were instructed to monitor their menstrual cycles for the next 6-12 
months for a spontaneous pregnancy.   
The primary  end-point of the study was the proportion of women without ovarian adhesions as 
evaluated by THL 180 days after the primary surgical procedure. Secondary end-point were the grade 
of ovarian adhesions and any peri- and post-operative complication. Grading of adhesions was as 
follows: grade 1: filmy avascular; grade 2, dense or vascular; grade 3, cohesive (145).  
Adhesions not involving the ovaries were not the object of this study.     
Considering an adhesion formation rate of 60% in the laparoscopic group (146) and hypothesizing a 
reduction of 20% of this rate in the THL group, we calculated that a sample of 194 patients would 
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have been sufficient to reject the null hypothesis (i.e. adhesion formation equal in the two groups) 
with a statistical power of 80% and an alfa error of 5%. Hypothesizing that 25% of patients would 
have refused to undergo the follow-up THL procedure, we recruited 123 patients per group.  
Statistical analysis was performed using the Social Package for Social Sciences (SPSS, Chicago, II, 
version 17.0). Data distribution for continuous variables was assessed with the Shapiro-Wilk’s test. 
Student’s t test for paired was used to compare these variables, which all showed a normal 
distribution. Differences in proportions between groups for categorical variables (presence of 
adhesions, grading of adhesions) were analyzed with the 2 test. 
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3.3 Results  
The flow of patients is reported in Figure 1. All patients received their allocated intervention. 
Analysis was carried out on an intention-to-treat basis. Baseline demographic, clinical and hormonal 
data of the patients included in the study are given in Table 1. No significant differences were 
observed between the two groups. Duration of the procedure was significantly shorter in the THL 
group in comparison with LOD group (p < .0001) (Table 2). No intra- or post-operative complication 
was observed in any patients in both groups. 
Table 2. Demographic, Clinical, and Hormonal Data. Values are given as mean ± SD  
Variable THL 
(n = 123) 
LOD 
(n = 123 ) 
p 
 
Age (years) 
 
27.5 ± 6.8 
 
30.1  ± 7.5 
 
ns 
BMI (kg/m
2
) 27.3 ± 5.6  25.9 ± 7.1  ns 
Procedure duration (mins) 
Duration of infertility (years) 
Pre-treatment with metformin (%) 
 CC cycles (months)                                                      
AMH (ng/ml)  
Testosterone (ng/ml) 
Androstenedione (ng/ml) 
DHEA sulphate (ng/ml)   
20 ± 10  
1.95  ± 0.8 
45.8 ± 2.1 
7.6 ± 1.36 
5.84 ± 1.16 
1.2 ± 0.3 
1.5 ± 0.2 
6.0 ± 0.8 
40 ± 20 
2.15 ± 0.6 
53.6 ± 1.3 
6.9 ± 1.32 
6.06 ± 1.18 
1.6 ± 0.2 
1.6 ± 0.2  
6.2 ± 0.9 
.0001 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
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Post-operative THL evaluation of ovarian adhesion formation 6 months after the original procedure 
was performed on 104 patients in group A and 97 patients in group B because 45 patients (19 group A 
and 26 group B) refused follow-up with THL. The analysis showed that 15 (15.5%)  patients in the 
THL group and 73 (70,2%) in the LOD group showed the presence of any type of ovarian adhesion. 
This difference was highly significant with a p value < .0001 and a relative risk of 0.22 [95%IC 
0.133-0.350]   
Among patients with post-operative ovarian adhesions observed at follow-up THL, 8 (53.3%) and 44 
(60.3%) showed filmy adhesions, 5 (33.3%) and 22 (30.1%) dense adhesions, and 2 (13.3%) and 7 
(9.6%) cohesive adhesions in the THL and LOD groups, respectively. Cumulative pregnancy rate was 
defined as percentage of pregnant patients, per total patients. The cumulative pregnancy was 
calculated according to time to the first event. In our study cumulative pregnancy rate after ovarian 
drilling was 68 %; no multiple pregnancy was observed and no differences in cumulative pregnancy 
was detected between groups underwent to the different surgical techniques. 
3.4 Discussion 
Our study showed that ovarian drilling using THL reduces post-operative ovarian adhesion formation. 
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Postoperative adhesions , fibrous connections developing between tissue and organs as a sequel to 
surgical trauma, have become the commonest complication of surgery and a source of major concern 
because of their  potentially dramatic consequences. Adhesions may produce disruption of the normal 
anatomy, thus altering normal tubal performance. Thus, follicular growth, pick-up of the oocyte after 
ovulation and spermatozoa or embryo transport may be impaired (147). Several women develop post-
operative adhesions after laparoscopy surgery. The most common site of post-operative adhesions 
formation is the ovary (147). Although several surgical measures and systemic pharmacologic 
treatments for adhesions prevention have been proposed the rate of peri-ovarian adhesion formation 
was not significantly reduced (148). The high incidence of post-operative adhesions and their clinical 
significance underline the importance of modifying the surgical technique in order to reduce potential 
adhesion formation (148).         
 Laparoscopic ovarian drilling (LOD) is a common surgical approach currently to treat 
anovulatory infertility in clomiphene (CC)-resistant women with polycystic ovarian syndrome 
(PCOS). The mechanism of action is still uncertain but likely lies in the reduction of ovarian 
androgen production through a decrease in stromal mass, or in the disruption of parenchymal blood 
flow (138). Nevertheless, two main drawbacks prevent LOD from being considered a primary 
approach to the treatment of PCOS: the risk inherent to any surgical procedure, and the risk of 
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adhesion formation potentially interfering with fertility (149). Indeed, one of the main shortcomings 
of LOD is postoperative adhesion formation due to bleeding from ovarian surface or premature 
contact between the ovary and the bowel after cauterization (146).    
 A number of studies have been designed to evaluate the rate of adhesion formation. As a 
result, currently, the incidence of postoperative adhesion formation range from 19% to 43% in some 
studies  and up to 82 % in other studies, but such wide variation possibly reflects an inadequate study 
design. Variation in the surgical techniques can obviously affect the rate of adhesion formation (150). 
The recent European Guidelines (2012) indicated the good surgical strategy to reduce adhesion 
formation: to reduce pressure and duration of pneumoperitoneum in laparoscopic surgery, to reduce 
risk of infection, to perform diligent haemostasis and ensure diligent use of cautery, to use frequent 
irrigation and aspiration when needed and reduce the time of surgery (151).    
THL was developed  as a less invasive alternative to conventional laparoscopy. THL may be 
considered as a less traumatic and more suitable outpatient procedure than diagnostic laparoscopy . 
This approach was recently proposed as a first line procedure in the exploration of adenexal structures 
in infertile women (152). In a recent study we have evaluated the pain during office THL and we have 
shown that office THL is well tolerated by patients (153).      
Some authors  reported the feasibility of ovarian drilling with THL  for anovulatory women with 
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PCOS to induce ovulation. [141, 154]. Fernandez et al. (141) suggest that THL with ovarian drilling 
using bipolar electrosurgery may be considered an alternative to conventional laparoscopy. In another 
study, Shibahra (155) investigated the postoperative endocrine alteration and clinical outcome of 
infertile women with PCOS undergone THL ovarian drilling, showing an improvement of the 
endocrine pattern.     
In a recent study, Franz et al. (156) investigated the learning curve of diagnostic THL and operative 
THL ovarian drilling with bipolar electro surgery in patient with clomiphene citrate-resistance. These 
authors showed that the learning curve of THL is comparable or shorter than traditional laparoscopy  
and encourage  to consider fertiloscopy as a first line in diagnostic work-up of infertile women and in 
clomiphene citrate-resistant PCOS for ovarian drilling. There are no data in literature on post-
operative ovarian adhesion formation after  THL ovarian drilling.  The only studies available 
evaluates adhesion formation after LOD. This is the first study comparing post-operative ovarian 
adhesion formation  after  LOD and THL in patients with PCOS using THL follow-up. Our data 
showed that after 6 months significant differences exists between the two groups in favor of THL.
       
The exact mechanism through which THL seems to induce adhesion in a lower proportion of patients 
is difficult to explain. It may be hypothesized that the use of saline solution instilled into the 
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peritoneal cavity during THL, the shorter duration of the procedure and avoiding the creation of 
pneumoperitoneum may contribute to this reduction. While laparoscopic surgery has been considered 
to be less adhesiogenic in comparison with laparotomy, in particular for the development of de novo 
adhesions, (157) a meta-analysis revealed comparable results for open vs laparoscopic surgery (157).  
Factors influencing postoperative adhesion are the pelvis environment, and the pressure and duration 
of the pneumoperitoneum  (151).        
This study had some limitations. THL allows to visualize only the lower part of the pelvis and the 
posterior wall of the uterus, so the presence of anterior or cranial adhesions cannot be excluded. The 
not  exact number of  drilling points practiced in every patient but we have defined the number of 
ovarian puncture case by case depending on the size of the ovary .    
Another possible limitation of the study may be the different types of electro surgery  used in the two 
techniques: monopolar diathermy for LOD and bipolar diathermy for THL. On the other hand, we 
feel that this can be a significant bias for the primary outcome of this study, considering that the depth 
of the coagulation, as well as the total number of drills were similar between the two groups. 
Moreover, considering the studies published in literature (137, 158-160), where both mono- and 
bipolar electricity were used, there seems not to be differences in terms of adhesion formation 
between the two techniques.    
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Strengths of this study rely on its randomized design, with robust exclusion and inclusion criteria, and 
the use of a single operator for all procedures, eliminating  one of the most important factor 
influencing surgical outcomes and an objective tool for the evaluation of adhesion formation (office 
THL).            
In conclusion, this study seems to indicate that THL ovarian drilling may reduce the risk of  ovarian 
adhesion formation and could be used as a safe and effective option to reduce ovarian adhesion 
formation especially in CC-resistant, anovulatory patients affected by PCOS. Prospective 
comparative studies including more patients should be conducted to confirm our preliminary results, 
but we  are confident that this procedure may offered as a first-line therapy in treatment of 
clomiphene citrate-resistant infertile women with PCOS. 
4. OUTCOME 
Lastly, we evaluated the positive effects of THLOD on the ovulation rate 
4.1 III STUDY: Operative transvaginal hydrolaparoscopy improve ovulation rate after 
clomiphene failure in polycystic ovary syndrome 
Laparoscopic ovarian drilling (LOD) is considered by the ESHRE/ASRM PCOS consensus 
workshop, the second-line intervention in the CC-resistant PCOS patients [130, 136]. Some authors 
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underlined the fact that LOD can significantly increase the rate of ovulation and conception in the 
women with anovulatory infertility due to PCOS, without the risks of multiple pregnancy or ovarian 
hyperstimulation syndrome induced by pharmacological treatments (152, 161). 
Several studies assessed THL to be a successful technique for ovarian drilling (162, 163). Some 
authors have assessed the ovulation and the conception rate in CC-resistant PCOS patients who 
undergone LOD (161, 163). The aim of our study was to assess the ovulation rate, with mid-luteal 
progesterone level and ultrasound follicles monitoring, in PCOS CC-resistant patients undergone 
THL ovarian drilling (THLOD) 
 
4.2 MATERIALS AND METHODS 
A prospective observational study was performed in PCOS, infertile, CC-resistant patients who 
underwent THLOD between December 2009 and July 2016. The patients are defined as CC-resistant 
if the ovulation fails after receiving a dosage of 150 mg per day for five days beginning on the third 
day of menstrual cycle, for at least six consecutive cycles (136, 164). All participants met the 
Rotterdam consensus criteria for the diagnosis of PCOS (165). Inclusion criteria were: desire for 
pregnancy; patent fallopian tubes, confirmed by hysterosalpingography or hysteroscopic diagnosis; 
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normal semen analysis parameters of the patients’ spouses according to the criteria of the World 
Health Organization. Exclusion criteria were age 518 and 440 years; evidence of premature ovarian 
failure, previous ovarian surgery; endocrine anomalies other than PCOS (congenital adrenal 
hyperplasia, Cushing’s syndrome, previous administration of androgens and androgensecreting 
tumor), use of drugs affecting ovarian function (e.g. gonadotropin-releasing hormone (GnRH) 
analogs, danazol, estroprogestin, etc.) within the previous 6 months, pregnancy, fixed retroverted 
uterus; lateral displacement of the cervix; suspected pelvic tumor; vaginal infections; abnormalities at 
vaginal examination and transvaginal ultrasound; psychiatric conditions impairing the ability of the 
patient to cooperate, obliteration of the pouch of Douglas or inability to perform the vaginal exam or 
any other contraindication to THL. Patients who met the study criteria and agreed to participate in the 
study gave their written informed consent, according to the institutional review board (IRB) of the 
study institution. Before the surgical procedure, all patients underwent clinical examination, routine 
preoperative biochemical testing and a transvaginal pelvic ultrasound examination. Each participant 
after surgical treatment underwent blood sampling on days 20–24 of the cycle to measure serum Pg 
levels. Progesterone level 43 ng/mL was considered as ovulation (166 - 168). The endometrial 
thickness and follicle size were monitored on days 10, 12 and 14 of the cycle and the subsequent 
surveillance time point was adjusted according to the individual situation until ovulation. The 
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presence of ovulation was found only in those cycles in which the follicle reached at least 16 mm in 
diameter. Ovulation frequency and the highest mean follicular diameters during the monitoring were 
recorded. Both tests were repeated each month for 6 months after surgery. The serum hCG 
concentration was measured in case of amenorrhea longer than 45 days. Biochemical pregnancy was 
considered when hCG was 42.5 mIU/ml in the absence of menstruation, and clinical pregnancy was 
defined by a fetal heart beat monitored by ultrasound at 6 weeks of gestation. Twenty patients with 
PCOS were not included in the study: 15 who refused to undergo THLOD and five who did not meet 
the inclusion criteria. The remaining 123 patients who satisfied the inclusion criteria underwent THL 
ovarian drilling. All serum samples were stored at 80 C until assay. Assays for LH, FSH and Pg were 
performed by automated micro particle enzyme-immunoassay (Abbott Axsym analyzer, Abbott 
Diagnostic). The normal laboratory ranges for serum LH, FSH, LH:FSH on day 3 of the cycle in 
women of reproductive age were, respectively, 1–18 mlU/ml, 1.0–8.8 mlU/ml and 1. The normal 
laboratory ranges for serum Pg on luteal phase were 3.28– 38.63 ng/mL. A single surgeon who had 
already performed over 50 procedures prior to this study performed surgical procedures. 123 patients 
underwent ovarian drilling with THL. THL was performed with the patients in gynecologic position, 
under spinal anesthesia. Using a Verres needle, 300 ml of normal saline solution was instilled into the 
peritoneal cavity through the posterior vaginal fornix. A specially designed needle dilating trocar 
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system with a total diameter of 3.9 mm was placed 10–20 mm below the insertion of the posterior 
vaginal wall to the cervix. A 2.7 mm diameter semirigid endoscope with a 3.5 mm sheath was used 
with an optical angle of 30 to visualize the pelvic cavity (Karl Storz, GmbH & Co., Tuttlingen, 
Germany). The posterior aspect of the uterus was examined first, followed by the ovary and fallopian 
tube on each side. A bipolar electrosurgical probe (Versapoint- Gynecare Inc., menlo Park, CA) was 
introduced through the auxiliary channel of the sheath. By using this probe, the ovarian cortex was 
drilled in 3–6 points per ovary, using a power setting of 110–130 W. All subjects received antibiotic 
prophylaxis immediately before the procedure (cefazolin 2 g intravenously). Data analysis was 
performed using the SPSS 20.0 software package (SPSS Inc. Chicago, IL). Data were evaluated for 
distribution by Shapiro–Wilks’test. Data were shown as mean ± standard deviation or as percentage.  
4.3 Results  
One hundred and seventeen patients completed the study protocol, since six patients were lost to 
follow-up. Two patients decided to postpone pregnancy and started contraceptive therapy. Other four 
patients decided to start a PMA program. Patient’s mean age at enrollment was 29.5 years ± 3.9 (SD). 
Hormonal profile at baseline was LH: 8.85 ± 1.39 mlU/ml; FSH: 5.35 ± 0.71 mlU/mL; LH:FSH ratio 
1.68 ± 0.35. Mean ovarian volume at baseline was 11.78 ± 1.61 cm3 . Ovulation rate at the follow up 
was 64.1% one month after treatment, 79.5% after three months and 82.9% after 6 months (Figure 3). 
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82 patients conceived during follow-up period. Pregnancy rate was 70.1% (Figure 3). Hormonal and 
clinical data after TVHLOD at ultrasound examination at 6 months follow up are shown in Table 3. 
Mean major follicular diameter during ovulation monitoring was 16.37 mm.  
Table 3. Hormonal and clinical data at ultrasound examination during 6 months follow up. 
_____________________________________________________________________________ 
        Study group post TVH-OD (N ¼ 117)  
Mean follicular diameter (mm)      16.37 ± 4.27  
Endometrial thickness (mm)       7.08 ± 2.25  
Pg levels (ng/mL)        17.39 ± 10.65  
______________________________________________________________________ 
Data are shown as mean ± standard deviation. 
 
 
FIGURE 3: Ovulation and pregnancy rate during follow up period. Data are shown as cumulative percentage from baseline to 6 months 
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4.4 Discussion 
 The aim of this study was to evaluate the feasibility and the efficacy of THL ovarian drilling in terms 
of ovulation rate and pregnancy rate in PCOS CC-resistant patients. From our study, these techniques 
have shown to be a feasible and efficacy option for ovarian drilling which allows an improvement of 
ovulation rate, evaluated by mid-luteal progesterone level and ultrasound monitoring, in CC-resistant 
PCOS patients. To the best of our knowledge, this is the first study that evaluates ovulation rate after 
THL ovarian drilling (THLOD) in those patients, by measurement of serum progesterone levels and 
US monitoring. Previously, studies have reported the effects of LOD on ovulation rate, demonstrating 
a value between 60 and 80% and evaluating ovulation rate by ovarian ultrasound and by measurement 
of progesterone on 21 day [16–18]. Zahiri Sorouri et al. evaluated the ovulation rate in CC-resistant 
PCOS patients who undergone LOD using serum progesterone levels. The authors showed an 
ovulation rate after LOD between 60% and 64.4% six mount follow up, on day 21 by measurement of 
progesterone, considering the level of Pg43 ng/mL as sign of ovulation (168). Our study has shown 
an ovulation rate of 80%, six months after THLOD treatment in CC-resistant PCOS and without 
hormonal stimulation, comparable with LOD. Many authors have reported not only high ovulation 
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rates (80%), but also high pregnancy rates (60–70%) following LOD (169 - 173). We have shown a 
pregnancy rate of 70% in patients undergone THLOD, comparable to these data. This data are in 
agreement with the work by Fernandez et al. (141) that have shown a cumulative pregnancy rate of 
70% after 6 months, and Gordts et al. (152) that reported a pregnancy rate of 85% after the procedure. 
It has been also shown that THLOD improves endocrine pattern in PCOS patients; in particular, THL 
is responsible for decreasing serum LH levels as well as LH/FSH ratio, without inducing a 
modification of serum FSH levels (174). In addition, a similar trend was reported in the reduction of 
serum AMH levels after THL, as observed after LOD. This finding may indicate that the mechanism 
of action of THLOD is similar to those occurring after LOD (174). Moreover, the high pregnancy rate 
and ovulation rate of THL comparable with LOD add an additional benefit in the use of these 
techniques especially in patients that require a tubal patency evaluation with the advantages that it can 
be performed without general anesthesia. To the best of our knowledge, no studies have assessed the 
effect of THLOD on ovulation rate using both the measurement of Pg levels and US monitoring. We 
have demonstrated that Pg levels in post-luteal phase after THLOD were 17 ng/mL. THL has been 
developed as a less invasive alternative to conventional laparoscopy in infertile PCOS patients (175). 
Several authors have proposed THL as the first-line procedure in the exploration of the infertile 
patients because it allows a direct access and an accurate visualization of ovaries, Fallopian tubes and 
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ovarian fossa (176, 177), with the opportunity of minimally invasive operative procedures (178, 179). 
This study shows further advantages of THLOD compared to LOD in the treatment of PCOS CC-
resistant patients: the reduced risk of postoperative adhesion formation, the low morbidity of the 
procedure, the safety and the advantage of transvaginal access in obese patients, the possibility of not 
having to perform it with general anesthesia, and also the advantages in term of cost, comfort and 
length of hospital stay compared to LOD. Moreover, in a recent study we have assessed that THLOD 
is better tolerated by patients than LOD (180). The limitation of this study is the relatively small 
number of patients undergoing operative THLOD; nevertheless, THL is an invasive procedure and, as 
such, cannot be imposed to patients unless clear indications to the procedure. Moreover, a possible 
selection bias may be present because the design is not randomized. On the other hand, the limited 
number of CCresistant PCOS patients who agree to undergo a surgical procedure makes it very 
difficult to set up such a study.The strengths of this study rely on its robust inclusion and exclusion 
criteria, the use of a single operator for all procedures, a long follow-up period of 6 months and the 
double evaluation of women undergone to THLOD both with USG monitoring and with Pg serum 
levels. In conclusion, our study shows that THLOD improve ovulation and pregnancy rate in women 
with CC-resistant PCOS; based on our data and previous studies, we believe that THLOD should 
mean an option in the management of anovulatory CC-PCOS patients and should be offered as 
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second-line therapy at all women who fail the medical methods of ovulation induction. Prospective, 
comparative studies including more patients should be undertaken to confirm our results. 
5. Conclusions 
In conclusion, our studies show the new approach to the conservative treatment of uterine malignant 
lesions and our commitment will be to continue on this line of research to investigate further 
conservative approaches and to improve the follow-up of these issues. 
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